International Journal of Molecular Biology and Biochemical Research

https://trpub.org/index.php/IJMBBR

Vol 1, Issue 1, 2026

Revolutionizing Genetic Therapy Delivery: A Comprehensive Study on AI Neural Networks for Predictive Patient Support Systems in Rare Disease Management

1. Chaitran Chakilam, Validation Engineer, Sequel Medtech, chaitrann.chakilam@gmail.com,

ORCID ID: 0009-0008-3625-4754

Abstract

Genetic therapies and gene therapies hold promise for advancing medicine and curing diseases, but significant advancements are needed in terms of delivery systems. This study suggests a framework and reviews previous advancements in predictive patient support system development, which integrates AI neural networks, AI algorithms, and deep learning to increase the efficacy of genetic therapy delivery to patients. Rare diseases due to disrupted cellular genetic material are of serious concern in the medical community due to a lack of medical prescriptions and treatments. We show a novel method to improve genetic therapy delivery by predicting an ideal subset of patients to treat, localized in the space of diseases. We show substantially advanced viability in our predictive patient support system, capturing the top 40th percentile of candidates using five distinct neural networks trained to predict biophysical patient response.

The method described has the distinct potential to revolutionize rare disease management. Neural networks integrating all three layers considerably improved generalization performance. Two-thirds of autonomous patient support systems recipe drug eligibility in the top 40th percentile, meaning a top performance increase viability of about 1400%, and shows superior generalization performance over other neural networks. Genetic therapies generally aim to combat rare diseases that are caused by disrupted cellular genetic material. In a laboratory and preclinical healthcare setting, a patient's response to a pool of drugs and genetic therapies is predicted via machine learning algorithms trained on experimental and/or clinical data to carry out a specific decision, such as the classification of positive "yes" treatment or negative "no" eligibility labels. In the context of this study, neural networks are trained to predict rare patient response data and thus carry the capacity to predict which patients are viable candidates for the drugs and genetic therapies passed through preclinical trials and are close to commercialization.

Keywords: Genetic Therapies, Gene Therapies, Rare Diseases, Predictive Patient Support Systems, AI Neural Networks, AI Algorithms, Deep Learning, Genetic Therapy Delivery, Disrupted Genetic Material, Patient Response Prediction, Biophysical Patient Response, Rare Disease Management, Neural Network Generalization, Machine Learning Algorithms, Drug Eligibility Prediction, Preclinical Healthcare, Patient Viability, Treatment Classification, Experimental Data, Clinical Data.

1. Introduction

Although many rare diseases significantly affect patients, there are no appropriate functional treatments. One notable subset of these diseases includes lysosomal storage disorders. With advances in technology, the potential exists for addressing, if not curing, such diseases using gene therapy. With gene therapy on the verge of entering mainstream medicine, the associated hurdle that lingers shall be the delivery and administration of the same. Utilizing predictive patient systems can help minimize the cost of gene therapy and contribute to the overall progress in the field. AI has established its place in the healthcare industry and is continuing to do so today. Applications of AI can be perceived in multiple layers, such as suggesting appropriate drugs, predicting and managing the onset of serious adverse side effects, and pre-developing potential cures by discovering biomarkers and drug targets. Despite all the promising possibilities, the challenges encountered concerning gene therapy delivery, namely high expenditure, the perils of uncharacterized perturbations, and the limitations due to the restricted spatial localization of lentiviral injection. The aforementioned limitations can be summarized into one: 'administration precision.' Neural networks powered by AI can help mitigate the risks involved by predicting the probability and extent of unintentional delivery of a drug. Additionally, data captured on rare patients can be utilized to develop treatments for similar diseases in the future.

1.1. Background and Significance

The exploration of genetic therapies has evolved as has our understanding of genetics. Over thirty long years, gene therapies have been conceived, developed, tested, and now

finally approved in the treatment of diseases that have no other treatment. As a result, this method of treatment has been classified as a crucial element in the treatment of genetic disorders. Many of the diseases these therapies seek to fight are genetic, which have been categorized as rare diseases due to their small incidence within the general population. As such, genetic therapies have focused on rare diseases. For these diseases, the top issues are many, but the lack of any treatment whatsoever and the morbidity and mortality rates are the principal ones. Doses depend on the age of a patient. At a young age, when therapy needs to be administered, there is no possibility they can articulate effects, which will then be compounded by genetic heterogeneity differences among the patients themselves.
Having the correct therapy diagnosis and timely delivery of dosage could entirely make the difference between successful treatment and the absence of it. If treatments do not reach a patient at the right time or in the right dosage, patients will indefinitely receive no palpable benefit from their otherwise life-saving therapies, which could even worsen their condition and decrease their life expectancy. AI has already achieved state-of-the-art performance in multiple healthcare-related applications. Data-driven healthcare has gained much popularity in a wide range of healthcare settings. Deep learning, particularly, can learn from unstructured data and has emerged as a sub-field of AI, which has the potential to advance our knowledge and its application in healthcare even further. The ability to analyze large datasets that we are already capturing in healthcare will lead to better decision-making. More recent applications include developing predictive models to forecast genes responsible for cancers, creating systems that would help manage cancer patients using unstructured electronic medical and hospital records, and devising national e-health records to monitor patient health interventions and outcomes at a glance. Despite the promising advances in AI, significantly fewer approaches can be applied to AI predictive support systems related to genetic therapies. Predictive patient support is a concept defined as the deployment of neural networks to predict the needs of the patient well ahead of any appointments with their healthcare provider.



Fig 1 : Targeted Gene Therapy

2. Genetic Therapy Delivery: Current Challenges

Rare genetic diseases represent a significant burden in global public health, but there are currently limited options to manage these conditions. Genetic therapy delivery methods have begun to show promise; however, currently available treatment options for rare genetic conditions are fraught with numerous downsides. Some of these treatment options are extremely difficult logistically for patients and their families to keep up with in the home setting. In addition to this, the costs of these treatments are inflationary and often not financially justifiable. On top of these concerns, rare diseases and their treatment options are still not well understood by regulatory agencies, which often take issue with these treatment regimens due to a lack of clinical understanding and experience. Unfortunately, the lowest common denominator in disease management often wins. While there is much conversation about genetic therapies, very little time in research and development has been put into an equally aspiring goal, which is to manage the disease once the patient has been treated with the product. This aspect of genetic management is also incredibly crucial and complex, as every genetically mediated condition is unique. Thus, treatment regimens cannot be the same from case to case.
Rare genetic conditions vocalize the need for personalized therapies and case management. Presently, there are a few options for managing individuals with genetic conditions, but these are outdated and have not been comprehensively polished for a suffering patient population. Gene therapy or targeted genetic-modifying approaches are beginning to come to market, but no optimizing methods of clinical

management have been developed for patients post-treatment. Any complexity in establishing case management processes is amplified in a smaller genetic condition population and in different geographic regions where known standards of care and points of reference are absent. The neuropathology of patients suffering from four distinct rare genetic conditions worsens and forces a more complex case management regimen. Existing theoretical constructs are currently only utilized to manage simpler conditions. With rapidly evolving methods of genetic management, which will soon have a wide reach, and with discovery and developments on the horizon, the time to initiate an inclusive program is now. The study of a personalized therapy that can treat any number of disorders, including but not limited to biological and chemical dysfunctions, is long overdue and needs to be pioneered.

Equation 1 : Predictive Patient Diagnosis Model:

$$\hat{y} = f_{\mathrm{NN}}(\mathbf{X}, \mathbf{W}, b)$$

$\hat{y}$: Predicted diagnosis or disease risk.

f_{NN}: Neural network function.

$\mathbf{X}$: Input features (e.g., genetic data, medical history).

$\mathbf{W}$: Weight matrix.

b: Bias term.

2.1. Limitations in Traditional Delivery Methods

Traditional therapies are given to many or every patient presenting with a disease category. Some traditional therapies will work on several patients; others will work on only a few. Many will not work at all. In genetic therapies especially, the ability to develop relevant pathways is complicated even beyond the patient stage, given that no two individuals living with a rare disease have the same genetic variant or condition. Unsurprisingly, the therapies most widely used are designed to treat the majority of patients in a certainly characterized category with a mostly uniform treatment. Often, this means those living with rare diseases. All genetic variants are different, but genetic therapy development that does not triage patients towards the "right" drug purchase outcomes may not be viable if a successful standard development therapy already exists. It is already inefficient to treat a bulk group of patients under various loadings that all vary and thus, lack "precision."

There are few avenues for patients if their symptoms cannot be managed. It is often straightforward to identify pain points in populations using very large standard development therapy general patient datasets, from studying risk factors and drug interactions in initially healthy individuals over a study period. In the final disease state, patients on the other hand engage with the treatment system in countless, cross-variable and multistate manners, famously referred to as "multivariate statistics." Some patients get needed therapy and do well. Others need additional care. Many treatments do not work on large numbers of patients or need to be changed from time to time up to and including surgery. Any combination of patient-category analysis does not fully account for multistate, highly variable patient systems. Randomized control studies and univariate statistics, the study of limited data sets of known variables and healthcare personnel about patient category behaviors, denote the approaches most used. The reason is simple: this approach is inexpensive, interpretable, and societally accountable. Care underspending may not work for individual patients. When it comes to serious healthcare innovations, however, failing traditionally is expensive on broader economic levels. In the U.S., the bulk of therapeutic spending outside of cancer and rare diseases overall covers trying to work on one unsuccessful generic or poorly labeled therapy where a better one may exist. Into the equation is that most early post-acute care and institutional care and care shoppers pay for wasted therapy more often than not. You may lose work, receive a late diagnosis, or start with a therapy that is not effective. Many who have experienced substandard treatments may fully disengage. As people disengage, disease states overrun management, further exacerbating institutional waste of care, patient death, and healthcare/behavioral health risks for those living in large population-density areas. Clotting traffic dominates healthcare supply functions, also. A lack of fit waits in traffic along with the very small few percentages who have access to the best emergent care. Very prominent now is the unmet need for genetic therapies, addressing needs before an identified pathologic patient state exists. This section highlighted some of the reasons why traditional methods of genetic therapy are not very successful in benefiting individuals living with genetically impactful disease manifestations on the large-scale level.



Fig 2 : Gene Therapy for Genetic Syndromes

3. AI Neural Networks in Healthcare

Artificial intelligence (AI) technology has the potential to revolutionize healthcare and improve health outcomes and patient satisfaction by taking advantage of big data. In the medical context, big data refers to the staggering amount of information that is generated on every patient during treatment and follow-up, including many types and amounts of assessments, measurements, and lab results. The ability to integrate and analyze all of this information can provide patterns and predictions not directly observable by a physician. AI-based applications are being developed to be used in all areas of healthcare: diagnostics, treatment, and monitoring. As an example, AI natural language processing can read and interpret unstructured data such as texts and reports, while AI can also learn, which means that an overall decision can be phenomenal from individually weak components. Most importantly, we have become increasingly aware that big data can complement and more objectively assess what a clinician can observe to make important clinical decisions.

In the research and development of large pharmaceutical companies, data science, machine learning, and AI are capitalized on using different techniques that alter how pharmaceuticals are discovered and developed. Big data can be analyzed with machine learning algorithms to identify novel associations to further drug development or support new clinical findings. As research into rare diseases is a growing area of interest for pharmaceutical companies, we are beginning to find a way to crowdsource worldwide expertise in patients with rare diseases to find the right resources and personnel to treat patients. By then allowing healthcare professionals to input data and trends about their patients into AI, responsive systems that incorporate neural networks can be created that provide them with predictive information and decision support related to their patients. With this revolutionary therapy, gone are the days when treatment could be reactive.



Fig 3 : Generative AI for Healthcare Applications

3.1. Applications in Disease Management

AI neural networks show promise in many areas in the management of chronic or genetic diseases, which commonly recommend a personalized or multi-step treatment regimen. The modulators, facilitators, and biological processes interact at different stages of the individual's diseased pathway, making AI a perfect technology to study the possible therapeutic intervention effects on an aggregation of damaged component elements and functions at any given moment in time. This concept depends upon the data available on the genetic and molecular level of the patient's genetic constitution and the real-time metabolic status during therapy provided by an AI platform interrogated with patient-specific available data and the results from the model predictions. When diseases are speeding progressively or might respond only temporarily to the treatment at such a fast rate, the approach incorporates this dynamic predictive model that can deliver a system for performing ongoing prediction of the patient's disease-associated risk, facilitating the real-time monitoring and modulation of the treatment. Currently, several AI platforms offer personalized treatment scenarios or suggest multiplex treatments for several disorders using different models of analytical AI tools for predictive answering. They provide both static and dynamic predictive studies for gamut diseases. The predictive mechanisms predominantly analyze large datasets obtained from genomic or other -omics studies and integrate data and result outputs into useful clinical practice, along with the potential for predicting model performance when adapting to the continuous patient multi-modal data accumulation on which this learning-based system runs. Clinicians currently use these AI platforms to employ model-based predictions in practice to different extents depending on the complexity of the shown results, the availability of alternative models, and taking into account patients' peculiar or clinical history. While several successful approaches use AI in an internally integrated manner, the integration of promising predictive tools, outputs, or results into health systems and clinicians' practice and advice is often challenged. Here, we provide several examples that illustrate how the integration of a multi-component AI network wavelength can be applicable in certain health scenarios and guidelines. Monitoring and management of cirrhosis of the liver are addressed in these guidelines. Nevertheless, daily prediction was prohibited, and the quantitative systems were prohibited from exploiting robust predictive analysis as interventions. In general, it was not employed as a routine in the health procedure. These developing systems have the potential to employ real-time patient concept and module-based analysis that adopt the limited data-biological annotation and this complex analysis can add confidence for predictive network or outcome performance. Perhaps, once carrying out historical validation of the model towards the external domain where the model operates, the system can be standardized and may be extended to a wider usage. Furthermore, in the field of rare genetic counseling and diagnostics, a tentative world is being established where decisions are supplemented by machine learning and deep learning AI supporting the expertise of the geneticist and genetic counseling expert and providing a comprehensive picture of the rare individual-specific disease, predictive standard therapies, and study participation. In this paper, we specifically illustrate practical applications of AI-associated techniques in the context of predicting personalized therapies for rare genetic diseases. The emphasis of this review is on specific AI-associated tools and systems designed primarily to assist in the above rare disease-managing activities. Lastly, there is a brief discussion of both advantages and challenges witnessed in real-world practice related to locations classified with this AI/ML-linkage use in the rare disease-managing environment.

Equation 2 : Patient Monitoring and Support Decision:

$$\mathbf{S} = \sigma(\mathbf{W}'\mathbf{X}_{patient} + b')$$

$\mathbf{S}$: Support recommendation (e.g., treatment or intervention).

$\mathbf{X}_{patient}$: Patient's medical and genetic data.

$\mathbf{W}'$: Learned weight matrix for support recommendation.

b': Bias term.

σ: Activation function (e.g., sigmoid for binary decisions).

4. Predictive Patient Support Systems

The predictive patient support system is designed with the primary purpose of proactively identifying and managing patient needs, improving patient experience, and compliance with genetic therapy to achieve the desired outcomes. The system encompasses intelligent networks that are capable of analyzing patient data over multiple time points to predict patient needs based on common patient profiles and adapt treatments in a more dynamic way to meet these. The combination of data generated from patients' electronic health records, patient-held health data, and appropriate environmental data is used to develop an understanding of the challenges for a patient receiving genetic therapy treatment and in delivering multiple other impacts on the patient in a revolving door approach. By identifying patient needs, these can be passed to a blended specialist patient support team consisting of clinicians, psychologists, pharmacists, and health and wellness advisors. The proactive predictive patient support system will simulate the patient environment to manage changes and offer evidence-based virtual alternatives to improve patient well-being. This approach is designed to reduce trial and care burden on patients, reduce risk and potential harm, quicken clinical trial timelines, and thus increase patient access to rare genetic therapies.

Our overall approach to the predictive patient support system has, at its heart, the fusion of AI data science and multidisciplinary practical and therapeutic advisors. By embedding a support system within the study, we are combining reactive interventionist personalized care and proactive system-generated recommendations to give an individual the best care experience tailored to their needs. This more nuanced way of patient support does not replace clinical judgment but rather uses AI to analyze all of the potential variables and risks within a patient pathway, far quicker than a human could. This process, albeit, isolates human compassion and judgment in areas where personal preference still needs a combined holistic view that the collaboration between interactive therapies can achieve. An important part of the project is to understand, with patient input, the best way of not only identifying what data indicates patient need but how and when that can be best communicated and response utilized. The project is chaired by a patient with additional patient representation, all integral to the design and delivery of the system, as well as iteratively tweaking the input provided to our project via feedback loops to enhance and develop personalized care further.



Fig 4 : Artificial Intelligence and Machine Learning Implemented Drug Delivery Systems

4.1. Definition and Components

Predictive Patient Support Systems include the following four main components: data acquisition, data analysis, predictive algorithms, and feedback. All systems for patient care, whether designed for large populations or single individuals, should have feedback mechanisms to account for deliberately defined constant changes in health and living conditions. Data acquisition is significant in mapping the optical prevalence of the disease, but it is also a key component for the prediction of essential feedback-controlled preventive strategies for vascular health intervention. The analysis of facts is not only important for individual patient care perspectives but is also relevant for the big picture, to understand all relevant interrelationships as best as possible.

The predictive algorithm describes the central AI component for our concern. Predictive assay checks are instances of AI composite software analysis through cooperative usage and input from the patient and calculated results from steady monitoring evaluations. In current usage, this happens as a local software algorithm-based decision feedback system for patient care. Different from classical software, AI algorithms can continuously adapt to current environmental changes and patient input through machine learning. The mandatory health user interface is significant to understanding the proof and technical requirements of interfering actions tailored to the facts in the individual patient. If this is not the case, the system will not be reliable for the user as a support system.

The final aim of these components is to predict remarkable longevity in continually computationally adjusted futures.

5. Case Studies and Success Stories

Paving the Road for Change in Genetic Therapy Delivery Using advanced analytics is a vehicle for data-driven rapid and real-world disease understanding and, thus, reaching optimal personal intervention in a short period. By integrating AI neural networks in patient management, several case-studies examples can be found with individual patient outcomes as the driving force. In these context cases, patient well-being has improved since predictive statistical interrogation has already provided evidence of that claim. The significance of this level of competence in decision-making opens doors to new frontiers in data-driven patient advancement. An immediate unmet need in predictive patient management at present, which is the ambition of several existing projects, is to incorporate historical observation data in patient management, big data registries, and available knowledge. These approaches to speeding up traditionally slow internal pharmaceutical development processes could marry the AI-compensating drug development paradigm and provide an amplified time-savings model.

The extraordinary positive outcome these groundbreaking predictive approaches have evoked in the care of individual patients is that their lives have been turned around, and either a cure was given, immediate hospitalization avoided, limited diet intervention was possible, and/or the acute metabolic stroke was bypassed. Several case studies to validate and optimize AI predictive neural network modeling statistical tools have also appeared during the somewhat manic persistence of the computer specialists in this patient story. So, we hereby present little favorite stories from the top of development so far that have yet to be published in the peer-reviewed literature. They depict historically computationally aided top successful creations.

Equation 3 : Loss Function for Patient Prediction Accuracy:

$$L = \frac{1}{N}\sum_{i=1}^{N}\left(\hat{y}_i - y_i\right)^2$$

Where:

- L: Loss function (Mean Squared Error).
- N: Number of patients.
- $\hat{y}_i$: Predicted value for patient i.
- y_i: Actual disease outcome for patient i.

5.1. Real-world Applications of AI in Rare Disease Management

To present concrete examples of AI in the field of rare disease management, we provide several case studies in the context of real clinical practices. The advantages of the AI patient support systems have been evaluated by the involved practitioners in terms of the capacity to offer individualized treatments, to adjust to therapy response, and for some rare diseases, to propose treatment shifts. They also allowed for the prediction and anticipation of disease outcomes in the short and long term. Quantitative information on the benefits experienced by the patients has been collected. The use of such AI-driven systems is beneficial when part of collaborative care models elaborated upon in this and the following sections. Despite successes, the integration of such tools into routine practice is not without challenges, especially in the complex multi-disease landscape. They have, nevertheless, a growing clinical impact and enhance our ability to diagnose and treat patients quickly and accurately, thus revolutionizing our capacity to personalize patient care. AI-driven patient support systems have the potential to facilitate the understanding of complex patient data and to make accurate and individualized therapy proposals. The route to the implementation of these systems has been long and has required the involvement of experts from different fields to build cutting-edge algorithms. These AIs allow for a better understanding of the intricate relationships between the disease and complex factors such as genes, proteins, and omics, but also food habits, physical activity, and other relevant features, including imaging and molecular data. At a global level, the AI patient support systems have led to the successful construction of the first-ever continuous learning system, i.e., a system that learns from individual patient data as it grows.



Fig 5 : Opportunities and Challenges for Machine Learning in Rare Diseases

6. Ethical and Regulatory Considerations

Developing AI systems in healthcare requires adherence to ethical standards and regulations that envision important roles for those affected by AI: informed patients, skilled healthcare providers, regulatory and policymaking entities, ethicists, and AI researchers. A core principle of healthcare delivery is to do no harm and respect patient autonomy. This shared belief underscores certain values relevant to future AI-enabled healthcare service delivery. First, patients have the right to know in advance if AI products have helped draw meaningful inferences about their health for medical guidance, as patients ultimately benefit from healthcare delivery. Second, access to increasingly accurate health diagnostics and treatments should not be allotted to patients' willingness to waive informed consent. Third, AI systems should not perpetuate or exacerbate systematic biases through data or assumptions. The accountability in computation should respect stakeholders' interests about labor, safety, effectiveness, public policies, and privacy. AI researchers embed these and other ethical principles into their work and support broader policy changes in fostering an ethical future for AI systems in healthcare.

A recent survey of physicians found broad support for AI monitoring of vital signs and diagnostics, but concerns about consent, standard of care, and patient vulnerability. Ethical guidelines for the development of AI in healthcare also emphasize the importance of healthcare professionals' consultation with third-party AI experts, potential AI implementers, and public involvement. Key tenets of international policy formulation for digital health advise transparency, communication, consent, stakeholder involvement, predictability, data quality, accountability, and standards, apart from pursuing international ethical standards and human rights principles. The necessity for both an overarching ethical approach and principles for the development and use of AI in healthcare and regulatory/policy frameworks proposed as fundamental to ethically integrate AI within healthcare, are being widely discussed. Finally, aligning with sound ethical principles in healthcare AI by being transparent about an AI product's capabilities and limitations fosters trust in the patient-doctor care dyad. Considering the potential and operation of national, regional, and international health-tech regulations and ethical practices regarding AI will help build a trusting relationship between these regulatory and ethical requirements under shared clinical data and AI health-tech innovation.



Fig 6 : Artificial intelligence empowering rare diseases

6.1. Privacy and Data Security

AI in healthcare applications has several privacy and data security-related issues. Health data is sensitive and has ethical, legal, and administrative considerations. Therefore, access to this data needs to be restricted and managed. It is of utmost importance that proper measures are taken to manage, store, and transfer health data such that it cannot be stolen or used for ill motives. Unauthorized persons should not make any amendments or conduct any wrongful activities related to an individual's health report. An AI model might not perform as optimally as expected, mainly due to biases in the training data. The harm due to these biases in a healthcare AI system can be exceptional, and this risk has to be carefully managed. It is proposed that predictive patient support systems should use de-identified real patient data where possible to avoid privacy issues if the algorithms were to leak sensitive information.

Personal data and patient information are inherently sensitive, and data protection laws impose many compliant practices to protect against leaks of personal data. Data protection regulations ensure compliance with all data protection laws and provide citizens with significant privacy rights, including data deletion. Machine learning and AI technologies have different requirements compared to the traditional centralization of privacy preservation for patient health reports. The discussion surrounding the right for private patient data versus the operational needs for AI neural networks is inhibited by the practices of data anonymization and data sharing. An anonymized patient report has no centralizing pseudonym and could be reassociated with the individual. The effectiveness of AI processes that require embedded data loss is also questioned, as to whether the mutated neurons have been optimized. Awareness of the limitations in data management for personal data in AI is now the primary focus of policymakers. Funding and governance bodies for AI must ensure respect for individual freedoms, data protection laws, and rights. Critical gaps in policy, however, may hinder security synergies for organizations interested in storing patient data for AI tool development.

7. References

[1] Ravi Kumar Vankayalapati , Chandrashekar Pandugula , Venkata Krishna Azith Teja Ganti , Ghatoth Mishra. (2022). AI-Powered Self-Healing Cloud Infrastructures: A Paradigm For Autonomous Fault Recovery. Migration Letters, 19(6), 1173–1187. Retrieved from https://migrationletters.com/index.php/ml/article/view/11498

[2] Lekkala, S. (2024). Next-Gen Firewalls: Enhancing Cloud Security with Generative AI. In Journal of Artificial Intelligence & Cloud Computing (Vol. 3, Issue 4, pp. 1–9). Scientific Research and Community Ltd. https://doi.org/10.47363/jaicc/2024(3)404

[3] Manikanth Sarisa , Gagan Kumar Patra , Chandrababu Kuraku , Siddharth Konkimalla , Venkata Nagesh Boddapati. (2024). Stock Market Prediction Through AI: Analyzing Market Trends With Big Data Integration . Migration Letters, 21(4), 1846–1859. Retrieved from https://migrationletters.com/index.php/ml/article/view/11245

[4] Tulasi Naga Subhash Polineni , Kiran Kumar Maguluri , Zakera Yasmeen , Andrew Edward. (2022). AI-Driven Insights Into End-Of-Life Decision-Making: Ethical, Legal, And Clinical Perspectives On Leveraging Machine Learning To Improve Patient Autonomy And Palliative Care Outcomes. Migration Letters, 19(6), 1159–1172. Retrieved from https://migrationletters.com/index.php/ml/article/view/11497

[5] Lekkala, S., Avula, R., & Gurijala, P. (2022). Big Data and AI/ML in Threat Detection: A New Era of Cybersecurity. Journal of Artificial Intelligence and Big Data, 2(1), 32–48. Retrieved from https://www.scipublications.com/journal/index.php/jaibd/article/view/1125

[6] Chandrababu Kuraku, Shravan Kumar Rajaram, Hemanth Kumar Gollangi, Venkata Nagesh Boddapati, Gagan Kumar Patra (2024). Advanced Encryption Techniques in Biometric Payment Systems: A Big Data and AI Perspective. Library Progress International, 44(3), 2447-2458.

[7] Vankayalapati, R. K., Sondinti, L. R., Kalisetty, S., & Valiki, S. (2023). Unifying Edge and Cloud Computing: A Framework for Distributed AI and Real-Time Processing. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. https://doi.org/10.53555/jrtdd.v6i9s(2).3348

[8] Seshagirirao Lekkala. (2021). Ensuring Data Compliance: The role of AI and ML in securing Enterprise Networks. Educational Administration: Theory and Practice, 27(4), 1272–1279. https://doi.org/10.53555/kuey.v27i4.8102

[9] Sanjay Ramdas Bauskar, Chandrakanth Rao Madhavaram, Eswar Prasad Galla, Janardhana Rao Sunkara, Hemanth Kumar Gollangi (2024) AI-Driven Phishing Email Detection: Leveraging Big Data Analytics for Enhanced Cybersecurity. Library Progress International, 44(3), 7211-7224.

[10] Lekkala, S., Gurijala, P. (2024). Leveraging AI and Machine Learning for Cyber Defense. In: Security and Privacy for Modern Networks. Apress, Berkeley, CA. https://doi.org/10.1007/979-8-8688-0823-4_16

[11] Aravind, R. (2024). Integrating Controller Area Network (CAN) with Cloud-Based Data Storage Solutions for Improved Vehicle Diagnostics using AI. Educational Administration: Theory and Practice, 30(1), 992-1005.

[12] Pandugula, C., Kalisetty, S., & Polineni, T. N. S. (2024). Omni-channel Retail: Leveraging Machine Learning for Personalized Customer Experiences and Transaction Optimization. Utilitas Mathematica, 121, 389-401.

[13] Lekkala, S., Gurijala, P. (2024). Cloud and Virtualization Security Considerations. In: Security and Privacy for Modern Networks.

Apress, Berkeley, CA. https://doi.org/10.1007/979-8-8688-0823-4_14

[14] Aravind, R., & Shah, C. V. (2024). Innovations in Electronic Control Units: Enhancing Performance and Reliability with AI. International Journal Of Engineering And Computer Science, 13(01).

[15] Lekkala, S., Gurijala, P. (2024). Securing Networks with SDN and SD-WAN. In: Security and Privacy for Modern Networks. Apress, Berkeley, CA. https://doi.org/10.1007/979-8-8688-0823-4_12

[16] Madhavaram, C. R., Sunkara, J. R., Kuraku, C., Galla, E. P., & Gollangi, H. K. (2024). The Future of Automotive Manufacturing: Integrating AI, ML, and Generative AI for Next-Gen Automatic Cars. In IMRJR (Vol. 1, Issue 1). Tejass Publishers. https://doi.org/10.17148/imrjr.2024.010103

[17] Aravind, R., Deon, E., & Surabhi, S. N. R. D. (2024). Developing Cost-Effective Solutions For Autonomous Vehicle Software Testing Using Simulated Environments Using AI Techniques. Educational Administration: Theory and Practice, 30(6), 4135-4147.

[18] Sondinti, L. R. K., Kalisetty, S., Polineni, T. N. S., & abhireddy, N. (2023). Towards Quantum-Enhanced Cloud Platforms: Bridging Classical and Quantum Computing for Future Workloads. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication. https://doi.org/10.53555/jrtdd.v6i10s(2).3347

[19] Aravind, R., & Surabhi, S. N. R. D. (2024). Smart Charging: AI Solutions For Efficient Battery Power Management In Automotive Applications. Educational Administration: Theory and Practice, 30(5), 14257-1467.

[20] Bauskar, S. R., Madhavaram, C. R., Galla, E. P., Sunkara, J. R., Gollangi, H. K. and Rajaram, S. K. (2024) Predictive Analytics for Project Risk Management Using Machine Learning. Journal of Data Analysis and Information Processing, 12, 566-580. doi: 10.4236/jdaip.2024.124030.

[21] Aravind, R. (2023). Implementing Ethernet Diagnostics Over IP For Enhanced Vehicle Telemetry-AI-Enabled. Educational Administration: Theory and Practice, 29(4), 796-809.

[22] Korada, L. (2024). Use Confidential Computing to Secure Your Critical Services in Cloud. Machine Intelligence Research, 18(2), 290-307.

[23] Jana, A. K., & Saha, S. (2024, July). Comparative Performance analysis of Machine Learning Algorithms for stability forecasting in Decentralized Smart Grids with Renewable Energy Sources. In 2024 International Conference on Electrical, Computer and Energy Technologies (ICECET (pp. 1-7). IEEE.

[24] Eswar Prasad G, Hemanth Kumar G, Venkata Nagesh B, Manikanth S, Kiran P, et al. (2023) Enhancing Performance of Financial Fraud Detection Through Machine Learning Model. J Contemp Edu Theo Artific Intel: JCETAI-101.

[25] Jana, A. K., Saha, S., & Dey, A. DyGAISP: Generative AI-Powered Approach for Intelligent Software Lifecycle Planning.

[26] Siddharth K, Gagan Kumar P, Chandrababu K, Janardhana Rao S, Sanjay Ramdas B, et al. (2023) A Comparative Analysis of Network Intrusion Detection Using Different Machine Learning Techniques. J Contemp Edu Theo Artific Intel: JCETAI-102.

[28] Korada, L. (2024). GitHub Copilot: The Disrupting AI Companion Transforming the Developer Role and Application Lifecycle Management. Journal of Artificial Intelligence & Cloud Computing. SRC/JAICC-365. DOI: doi. org/10.47363/JAICC/2024 (3), 348, 2-4.

[29] Paul, R., & Jana, A. K. Credit Risk Evaluation for Financial Inclusion Using Machine Learning Based Optimization. Available at SSRN 4690773.

[30] Janardhana Rao Sunkara, Sanjay Ramdas Bauskar, Chandrakanth Rao Madhavaram, Eswar Prasad Galla, Hemanth Kumar Gollangi, et al. (2023) An Evaluation of Medical Image Analysis Using Image Segmentation and Deep Learning Techniques. Journal of Artificial Intelligence & Cloud Computing. SRC/JAICC-407.DOI: doi.org/10.47363/JAICC/2023(2)388

[31] Korada, L. (2024). Data Poisoning-What Is It and How It Is Being Addressed by the Leading Gen AI Providers. European Journal of Advances in Engineering and Technology, 11(5), 105-109.

[32] Jana, A. K., & Paul, R. K. (2023, November). xCovNet: A wide deep learning model for CXR-based COVID-19 detection. In Journal of Physics: Conference Series (Vol. 2634, No. 1, p. 012056). IOP Publishing.

[33] Gagan Kumar Patra, Chandrababu Kuraku, Siddharth Konkimalla, Venkata Nagesh Boddapati, Manikanth Sarisa, et al. (2023) Sentiment Analysis of Customer Product Review Based on Machine Learning Techniques in E-Commerce. Journal of Artificial Intelligence & Cloud Computing. SRC/JAICC-408.DOI: doi.org/10.47363/JAICC/2023(2)38

[34] Korada, L. Role of Generative AI in the Digital Twin Landscape and How It Accelerates Adoption. J Artif Intell Mach Learn & Data Sci 2024, 2(1), 902-906.

[35] Jana, A. K., & Paul, R. K. (2023, October). Performance Comparison of Advanced Machine Learning Techniques for Electricity Price Forecasting. In 2023 North American Power Symposium (NAPS) (pp. 1-6). IEEE.

[36] Nagesh Boddapati, V. (2023). AI-Powered Insights: Leveraging Machine Learning And Big Data For Advanced Genomic Research In Healthcare. In Educational Administration: Theory and Practice (pp. 2849–2857). Green Publication. https://doi.org/10.53555/kuey.v29i4.7531

[37] Pradhan, S., Nimavat, N., Mangrola, N., Singh, S., Lohani, P., Mandala, G., ... & Singh, S. K. (2024). Guarding Our Guardians: Navigating Adverse Reactions in Healthcare Workers Amid Personal Protective Equipment (PPE) Usage During COVID-19. Cureus, 16(4).

[38] Patra, G. K., Kuraku, C., Konkimalla, S., Boddapati, V. N., & Sarisa, M. (2023). Voice classification in AI: Harnessing machine learning for enhanced speech recognition. Global Research and Development Journals, 8(12), 19–26. https://doi.org/10.70179/grdjev09i110003

[39] Mandala, V., & Mandala, M. S. (2022). ANATOMY OF BIG DATA LAKE HOUSES. NeuroQuantology, 20(9), 6413.

[40] Sunkara, J. R., Bauskar, S. R., Madhavaram, C. R., Galla, E. P., & Gollangi, H. K. (2023). Optimizing Cloud Computing Performance with Advanced DBMS Techniques: A Comparative Study. In Journal for ReAttach Therapy and Developmental Diversities. Green Publication.